Displaying drugs 6576 - 6600 of 8282 in total
Vatreptacog alfa
Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
Investigational
Matched Description: … Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia …
Evogliptin
Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment …
5-fluoro-2'-deoxycytidine
5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
Investigational
Matched Description: … 5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms …
Mavoglurant
Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Investigational
Matched Description: … Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant …
Avadomide
Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).
Investigational
Matched Description: … Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, …
Marzeptacog alfa (activated)
Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
Investigational
Matched Description: … investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of …
Elgemtumab
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of …
Bisphosphocin Nu-3
Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Sepofarsen
Sepofarsen is under investigation in clinical trial NCT03913143 (A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)).
Investigational
Matched Description: … trial NCT03913143 (A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of …
Tafolecimab
Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia).
Investigational
Matched Description: … Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of …
AB-201
AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
Investigational
Matched Description: … [L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric …
EDIT-301
EDIT-301 is an investigational cell therapy consisting of autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the gamma globin gene (HBG1 and HBG2).
Investigational
Matched Description: … EDIT-301 is an investigational cell therapy consisting of autologous CD34+ hematopoietic stem and progenitor …
Fazpilodemab
Fazpilodemab is under investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-alcoholic Steatohepatitis).
Investigational
Matched Description: … investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of …
Surotomycin
Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other...
Investigational
Matched Description: … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection ... acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of ... Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the …
Tengonermin
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. NGR-hTNF specifically targets angiogenic...
Investigational
Matched Description: … of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity. ... [A233265] It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis ... [A233270] A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing …
Ferric pyrophosphate
Ferric pyrophosphate is an iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate. It presents an increasing interest as this insoluble...
Experimental
Matched Description: … interactions of iron in plasma. ... side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of …
Dilmapimod
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been...
Investigational
Matched Description: … Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation …
Methylmalonic Acid
A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA. [PubChem]
Experimental
Matched Description: … A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. ... This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl …
Virginiamycin S1
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
Experimental
Matched Description: … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae …
rhIGFBP-3
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Matched Description: … It is developed by Insmed and is currently under phase I of the clinical trial. ... anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of …
Vicriviroc
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Investigational
Matched Description: … Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of ... This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells …
Displaying drugs 6576 - 6600 of 8282 in total